Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Medical Mutual

MINNEAPOLIS, Dec. 23, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Medical Mutual has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent^® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.  Medical Mutual is a large, regional private insurer with approximately 2.7 million covered lives, primarily in Ohio, as well as Georgia, Indiana, Michigan, Pennsylvania, South Carolina and West Virginia.

"This new policy reflects our continuing efforts to educate payers on the clinical benefits and cost effectiveness of Urgent PC therapy," said Nancy Kolb, Vice President of Healthcare Policy and Reimbursement.  "With the addition of Medical Mutual, we now have approximately 108 million lives covered by private payers and 40 million Medicare beneficiaries with access to Urgent PC therapy."

The policy is available on the Medical Mutual site at medicalmutual.com.

About Overactive Bladder

Overactive bladder (OAB) is a chronic condition that affects approximately 34 million US adults.  The symptoms include urinary urgency, frequency and urge incontinence.  The Urgent PC Neuromodulation System is the only FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy. 

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical company committed to offering transformative treatment options to specialty physicians.  Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent^® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique^®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information
This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.

SOURCE Uroplasty, Inc.